Fig. 2

Iron chelator DFOM alleviated the development of NAFLD by improving iron and lipid metabolism. a Schematic diagram of DFOM intervention. b Serum levels of AST and ALT from mice with or without DFOM treatment (n ≥ 4). c HE staining results of liver tissue with or without DFOM treatment. d The concentration of liver tissue Fe²⁺, serum ferritin and serum Tf with or without DFOM treatment (n = 4). e Prussian blue staining of the liver (n = 4). f, g Western blotting method detected the expression of FASN, Cav-1, HO-1 and Nrf2 in liver tissue with or without DFOM treatment (n = 3). ^*P < 0.05, ^**P < 0.01, ^***P < 0.001, as determined by one-way ANOVA. All data were shown as the mean ± SD. ns non-significant, DFOM deferoxamine mesylate, NAFLD non-alcoholic fatty liver disease, AST aspartate transaminase, ALT alanine aminotransferase, HFD high-fat diet, Tf transferrin, FASN fatty acid synthase, Cav-1 caveolin-1, Nrf2 nuclear factor erythroid 2-related factor 2, HO-1 heme oxygenase-1